RhumbLine Advisers’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-31,890
| Closed | -$118K | – | 2831 |
|
|
2017
Q4 | $118K | Sell |
31,890
-7,254
| -19% | -$29.7K | ﹤0.01% | 2755 |
|
|
2017
Q3 | $160K | Buy |
39,144
+750
| +2% | +$2.87K | ﹤0.01% | 2808 |
|
|
2017
Q2 | $143K | Buy |
+38,394
| New | +$152K | ﹤0.01% | 2849 |
|
|
2016
Q2 | – | Sell |
-16,409
| Closed | -$125K | – | 3062 |
|
|
2016
Q1 | $125K | Buy |
16,409
+29
| +0.2% | +$223 | ﹤0.01% | 2857 |
|
|
2015
Q4 | $218K | Buy |
16,380
+1,244
| +8% | +$21.4K | ﹤0.01% | 2749 |
|
|
2015
Q3 | $249K | Buy |
15,136
+608
| +4% | +$12.5K | ﹤0.01% | 2663 |
|
|
2015
Q2 | $326K | Buy |
14,528
+1,101
| +8% | +$17.4K | ﹤0.01% | 2604 |
|
|
2015
Q1 | $131K | Buy |
13,427
+3,892
| +41% | +$38.2K | ﹤0.01% | 2913 |
|
|
2014
Q4 | $109K | Buy |
9,535
+467
| +5% | +$5.07K | ﹤0.01% | 2949 |
|
|
2014
Q3 | $104K | Hold |
9,068
| – | – | ﹤0.01% | 2923 |
|
|
2014
Q2 | $176K | Buy |
+9,068
| New | +$160K | ﹤0.01% | 2880 |
|
RhumbLine Advisers's CASC Position: Q1 2018 in Review
RhumbLine Advisers sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 31,890 shares — an estimated $118K sold.
RhumbLine Advisers first reported a position in CASC in Q2 2014 and held it in 11 quarters. The position peaked at $326K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- RhumbLine Advisers reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- RhumbLine Advisers sold 31,890 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $118K.
- RhumbLine Advisers first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 11 quarters.
- RhumbLine Advisers's Cascadian Therapeutics, Inc. position peaked at $326K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on RhumbLine Advisers's 13F filing for Q1 2018, filed 2 May 2018.